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Abstract
Background: Non-steroidal anti-inflammatory drugs (NSAIDs) have long been suspected of negatively affecting
fracture healing, although numerous disputes still exist and little data are available regarding diclofenac. Glucocorticoids
interfere in this process over a similar and even broader mechanism of action. As many previously conducted studies
evaluated either morphological changes or biomechanical properties of treated bones, the conjunction of
both structural measures is completely missing. Therefore, it was our aim to evaluate the effects of diclofenac
and prednisolone on the fracture callus biomechanically, morphologically and by 3-dimensional (3D) microstructural
analysis.
Methods: Femura of diclofenac-, prednisolone- or placebo-treated rats were pinned and a closed transverse fracture
was generated. After 21 days, biomechanics, micro-CT (μCT) and histology were examined.
Results: The diclofenac group showed significantly impaired fracture healing compared with the control group by
biomechanics and μCT (e.g. stiffness: 57.31 ± 31.11 N/mm vs. 122.44 ± 81.16 N/mm, p = 0.030; callus volume: 47.05 ± 15.
67 mm3 vs. 67.19 ± 14.90 mm3, p = 0.037, trabecular thickness: 0.0937 mm± 0.003 vs. 0.0983 mm± 0.003, p = 0.023), as
confirmed by histology. Biomechanics of the prednisolone group showed obviously lower absolute values than the
control group. These alterations were confirmed in conjunction with μCT and histology.
Conclusions: The inhibiting effects of both substances were not only mediated by absolute parameters (e.g. breaking
load, BV), but we have shown, for the first time, that additional changes occurred in the microstructural bony network.
Especially in patients at risk for delayed bone healing (arteriosclerosis, diabetes mellitus, smoking), the administration of
these drugs should be weighed carefully.
Keywords: Fracture healing, Bone regeneration, Bone remodelling, Micro-CT (μCT), Histology, Biomechanics,
Bone volume (BV), Tissue mineral density (TMD)
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COX-1 and-2, Cyclooxygenase isoenzymes 1 and 2; DA, Degree of anisotropy; F, Fracture site; FCT, Fibrous
connective tissue; i.m., Intramuscular; LL, Laczkó and Lévai; mean ± SD, Mean values ± standard deviation;
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Background
In clinical practice, several medications offering pain
relief, anti-inflammation and a reduction of postopera-
tive swelling are applied after bone surgery or trauma,
although their potential side effects on bone healing
have not been studied adequately. Non-steroidal anti-
inflammatory drugs (NSAIDs) have for some time been
suspected to affect fracture healing negatively [1–4]
and might even cause bone loss after tooth extraction
[5]. However, numerous disputes still exist and limited
data are available with regard to diclofenac, which is
one of the most often applied substances in clinical use.
Through the inhibition of phospholipase A2, glucocor-
ticoids act earlier in the same pathway as NSAIDs.
Their possibly more serious consequences after short-
term use for humans have been insufficiently examined
in this context. They are known to affect bone remodel-
ling [6–8] and fracture healing in animal models after
long-term use [9, 10].
Recent molecular biological studies suggest that the
early bone healing phase is crucial for the definitive
success and stability of the bone [11]. This phase is char-
acterised by an inflammatory reaction of the body with
an increase in the secretion of prostaglandins (PGs) by
osteoblasts [12].
PGs are hormone-like substances with proinflammatory
effect and play a key role in fracture healing. The cycloox-
ygenase (COX) isoenzymes 1 and 2 (COX-1 and -2) con-
trol the production of PGs: COX-2 is specifically involved
in the inflammatory response, whereas COX-1 is rather
involved universally in various physiological processes,
such as platelet aggregation and cytoprotection in the
gastrointestinal tract. NSAIDs inhibit unspecifically both
the activity of COX-1 and -2 and effectively reduce pain
and inflammation [13].
In vitro, diclofenac acts negatively on osteoblasts at early
stages and appears to inhibit their function. This effect is
seen even at relatively low concentrations corresponding
to those commonly reached in vivo and might possibly
lead to a delay of bone healing [11, 13]. Additionally,
NSAIDs are used therapeutically to reduce heterotopic os-
sifications after elective joint-replacement or fractures,
strongly suggesting their potential to inhibit or negatively
affect endochondral ossification mechanisms [4]. Never-
theless, within the few animal studies previously carried
out, the reported influence of diclofenac on bone healing
is controversial and, thus, unclear [2, 13–15].
Physiological humane serum levels of glucocorticoids
have shown a maximum stimulatory effect on osteo-
blasts in vitro. However, increasing the dose in vitro to
supraphysiological doses leads to a decreased ability of
osteoblasts to differentiate [6]. Corticosteroid treatment
is commonly used in inflammatory and rheumatological
diseases and to reduce postoperative pain and prolonged
soft tissue swelling after elective surgery or accidental
trauma [16]. Unlike NSAIDs, which do not interfere
until the conversion of arachidonic acid to PGs in the
biosynthetic pathway, glucocorticoids inhibit the produc-
tion of arachidonic acid and thus interfere at an earlier
point than NSAIDs in this pathway [17]. Arachidonic
acid is the basis for the production of both PGs and leu-
kotrienes. In addition to the PGs, the latter play a crucial
role in the inflammation response of the body. Conse-
quently, glucocorticoids might lead to a (more) serious
delay of bone healing [7, 18, 19].
Both drugs are often administered in clinical use briefly
after surgery or trauma. Therefore, the combined results
of our study should allow to reduce uncertainties of
former studies concerning the impact of medication on
the early stage of fracture healing and should enrich our
knowledge of the way in which these drugs act. Unlike
precedent work, our evaluation was performed function-
ally, microstructurally and morphologically via the com-
bination of biomechanics, micro-CT (μCT) and histology.
Summarised, our main objectives were to examine
whether the tested substances (1) show the potential to
reduce the load bearing capacity of the fracture callus of
unstable mid-femural fractures expressed by a reduced
breaking load in the three-point bending and (2)
whether microstructural changes of the newly formed
callus are evident by μCT and histology.
Methods
Animal model
Adult male Wistar rats (n = 63, aged 16 weeks, mean
weight ± SD: 500 g ± 50 g) were purchased from Charles
River Laboratories (Sulzfeld, Germany) and acclimatised
for at least 2 weeks prior to experimentation. The an-
imals were singly fed, housed at 23–25 °C (humidity:
55 ± 5 %) with a 12-h light/dark cycle and allowed
free access to water and standard laboratory pellets.
Rats were randomised and allocated to the 3 different
arms (Diclofenac, Prednisolone or Control) each consist-
ing of 2 groups (Group A: biomechanical testing: total of
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33 rats; 11 animals for diclofenac, 11 for prednisolone
and 11 for controls; Group B: histology and μCT: total
of 21 rats; 7 animals for diclofenac, 7 for prednisolone
and 7 for controls).
Prior to the operation, the rats were anaesthetised
by intramuscular (i.m.) injection of Medetomidine
(Medetomin, 0.15 mg/kg, Dechra Veterinary Products,
‘s-Hertogenbosch, Netherlands), Midazolam (Midazolam,
2 mg/kg, Hexal AG, Germany) and Fentanyl (Fentadon,
5 μg/kg, Dechra Veterinary Products, ‘s-Hertogenbosch,
Netherlands). A Kirschner wire (K-wire; 1.0 mm) was
inserted into the medullary canal of the right femur in an
antegrade manner [20, 21] followed by a closed mid-
diaphyseal fracture. The procedure was performed as a
modification of the method first described by Bonnarens
and Einhorn in 1984 [22].
To end the anaesthesia after the operation, an antidote
combination was given subcutaneously (s.c.), composed of
Atipamezole (Antisedan, 0.75 mg/kg, Orion Corporation,
Espoo, Finland), Flumazenil (Flumazenil, 0.2 mg/kg, Hexal
AG) and Naloxone hydrochloride (Naloxone, 0.12 mg/kg,
Braun AG, Germany). During the postoperative period,
pain relief was performed by the subcutaneous adminis-
tration of buprenorphine twice a day (Buprenodale,
0.05 mg/kg, Dechra Veterinary Products) and the animals
were able to put weight on the leg immediately.
Depending on the group, daily subcutaneous adminis-
tration of diclofenac or prednisolone was performed.
The control animals received only sodium chloride solu-
tion subcutaneously. Drugs were administrated in the
following dosages:
Diclofenac (Voltaren-Resinat, Novartis GmbH): 5 mg/
kg BW per day s.c.
Prednisolon (Solu-Decortin H, Merck KGaA): 0,5 mg/
kg BW per day s.c.
Under anaesthesia with isoflurane, blood was taken 2–
3 h after the administration of the substances on day 5
from the venous angle to check the serum levels of the
medication.
Before the rats were sacrificed on day 21 by an over-
dose of Narcoren (sodium pentobarbital 80 mg/kg BW),
they were anaesthetised in a plastic box by inhalation of
isoflurane and, once more, blood was taken by puncture
of the heart to determine the serum levels of each drug.
Plain X-ray controls (anterior-posterior and lateral view)
were performed via c-arm (Siemens, Erlangen, Germany)
after intramedullary pinning, following the fracture (both
intraoperatively) and post mortem.
Depending on the group allocation, the bones were
fresh-frozen and stored at −20 °C (Biomechanical group)
or fixed in 100 % methanol (histology/μCT) and stored
at 4 °C. Analyses were carried out, after pin removal, ei-
ther by μCT or by biomechanics. All researchers involved
in this study were blinded throughout the evaluations.
Biomechanics
Three-point bending was performed by using a Wolpert
TZZ 707/386 material test machine (Istron Wolpert
GmbH, Darmstadt, Germany, Fig. 1a). According to
Turner et al., the distance between the bearing and load-
ing bars for each rat femur was 15 mm for 3-point bend-
ing [23]. The femurs were placed horizontally with the
anterior surface upwards.
Bending load was applied constantly with a displace-
ment rate of 5 mm/min and directed vertically to the
mid-shaft of the femur until failure (breaking load). The
termination criterion was defined as a reduction in the
force of > 50 N, whereas the failure criterion was defined
as a reduction in the force of 80 %. The breaking load
(N) and stiffness (N/mm) were determined from the
load-displacement diagram (highest point or regression
Fig. 1 Biomechanical testing. a Three-point bending by using a material testing machine. b Breaking load (N) and stiffness (N/mm) were determined
from the load-displacement diagram (highest point or regression of the curve)
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of the curve) (Fig. 1b) by using the test program Test&-
Motion (DOLI Elektronik GmbH, München, Germany).
Failure load and stiffness were collected for each
femur of the biomechanical group. Absolute and rela-
tive values [failure load and stiffness of the experimen-
tal side (n = 30) in relation to the intact contralateral
bone (n = 30) as a percentage (%) of the intact load or
stiffness] were determined.
Micro CT
The femura were scanned by using an isotropic voxel
size of 10 μm (55 kVp, 145 μA; μCT 40, Scanco Medical,
Brüttisellen, Switzerland). The integration time was set
at 200 ms. Images were reconstructed with 2048 ×
2048 pixels per cross section. Before the measurement, a
scout view was obtained and the scanning area of
620 μm (slice increment: 10 μm) covering both sides of
the fracture gap (each 3.1 mm) was determined within
two reference lines (Fig. 2a and b).
Thresholds were determined visually by two independ-
ent examiners (based on histograms) to separate original
cortical bone from callus, marrow and solution [24]. Dif-
ferences in the brightness of the pixels were evident
(Fig. 2c and d). A constrained 3D Gaussian filter was
used to suppress partly the noise in the volumes. The
grey-scale images were segmented by using the same pa-
rameters for callus [sigma (0.8), support (1) and threshold
(150)] and original cortical bone [sigma (1.5), support (3)
and threshold (370)]. After reconstruction of the data, the
analysis of the micro-structural parameters was performed
on the basis of the selected volume of interest (VOI) to
obtain the 3D evaluation. A standard convolution-
backprojection procedure with a Shepp and Logan filter
was used to reconstruct 3D CT images (Fig. 2e and f ).
All image processing steps were conducted automatic-
ally by using Image Processing Language (IPL, Institute
for Biomedical Engineering, ETH and University of
Zürich). The following non-volume-depending parame-
ters (as metric characteristics) were determined: the
bone volume (BV, mm3), tissue mineral density (TMD,
mg HA/cm3) and bone mineral content (BMC, defined
as the callus BV multiplied by TMD, mg) [25] and the
structure model index (SMI, dimensionless), degree of
anisotropy (DA, dimensionless), bone surface (BS,
mm3) and trabecular thickness (Tb. Th., mm) as struc-
tural parameters.
Histological analysis
After μCT analysis, the specimens were dehydrated in a
graded series of ethanol (from 70 to 100 % [v/v]) and
acetone and were then embedded in methyl methacryl-
ate (MMA). After polymerisation, undecalcified sections
of the MMA-embedded samples of 100 ± 20 μm in
thickness were prepared by using a sawing microtome
(Leica, Wetzlar, Germany) technique. Sections were cut
coronally through each sample. Selected specimens were
additionally ground (70 μm) and polished (Schleifsystem
400 CS, Exakt, Norderstedt, Germany). For histological
analysis, the sections were surface-stained as described
by Laczkó and Lévai (LL) [26]. For overview images, a
Wild® Macroscope M3Z (Wild, Heerbrugg, Switzerland)
was used in motion function and analysis was performed
via bright-field microscopy (Axiophot 2; Zeiss, Jena,
Germany). Detailed images were digitised with a micro-
scope (Nikon Eclipse 50i; Nikon, Düsseldorf, Germany)
and video camera (AxioCam HRc; Zeiss, Jena, Germany;
magnification 10x). Semi-quantitative analysis was car-
ried out by using an image analysis system (Axiovision
4.8, Zeiss, Jena, Germany) modified from [14, 20]. In de-
tail, the area of the fracture gap of two central sections
Fig. 2 Scout view (a) and determination of the scanning area within
two reference lines (b). 2D axial μCT (c) grey value image of original
cortical bone, callus and air/bone marrow and (d) corresponding full
automatically segmented image (callus = red); 3D coronar μCT
half-sliced (e) and overview image (f) (Two Thresholding Procedure,
callus blue and semitransparent and cortical bone grey)
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was examined. We semi-quantitatively evaluated whether,
in the respective area cartilage, connective tissue or newly
formed bone was present. This was described as a per-
centage of all the samples of each group with the respect-
ive tissue. Furthermore, we investigated whether bony
bridging of the fracture gap appeared. This was reported
as a percentage of all the samples of each group.
Statistical analysis
A power analysis was used to determine the number of
animals needed for the biomechanical workup [27]. A
two group t-test with a 5 % two-sided significance level
has 80 % power to detect an effect size of 1.38 (or 1.26)
when the sample sizes in two groups are 8 (or 11) and
11, respectively (nQuery Advisor 7.0). With regard to
μCT and histology, a minimal sample size of 6 animals
was chosen for exploratory investigations and the com-
putation of descriptive statistics with no need for a
power calculation.
Statistical analysis was carried out by using R 3.1.0
(The R Foundation for Statistical Computing, Vienna,
Austria) and GraphPad Prism Version 4.00 (GraphPad
Prism Software® San Diego, USA). Differences between
the treatment groups were assessed by unpaired two-
sided Student’s t-tests. All tests were conducted on ex-
ploratory 5 % significance levels. The distribution of
quantitative data was imaged as mean values ± standard
deviation (mean ± SD).
Results
Inclusions and exclusions
All in all, 49 of the animals could be included in the
study. No infection, weight loss ≥ 5 % or severe swelling
was observed. 14 of 63 (22 %) had to be excluded be-
cause of various complications (no fracture, comminuted
fracture or wrong localisation of the fracture).
Serumlevels
Diclofenac blood levels were determined to be within
the target range (0.1–2.5 μg/ml; Medizinisches Ver-
sorgungszentrum Dr. Eberhard & Partner, Dortmund;
first blood draw: 1.34 μg/ml; second blood draw: 2.33 μg/
ml, averages).
Prednisolone blood levels were also determined to lie
within the target range (30–400 ng/ml) detectable (first
blood draw: 94.05 ng/ml; second blood draw: 40.01 ng/
ml, averages).
Biomechanics
Thirty animals (60 femura) were eligible for biomech-
anical testing.
Regarding the breaking load, the Diclofenac and pred-
nisolone groups showed obviously lower values than the
control. In detail, the breaking load of the experimental
sides exhibited 77.65 N ± 41.82 N for the controls,
61.97 N ± 24.91 N for the diclofenac group and 54.30 N
± 28.68 N for the prednisolone group (Table 1, Fig. 3a).
The percentage of the intact load revealed 0.36 ± 0.16 for
the controls, 0.30 ± 0.12 for the diclofenac group and
0.29 ± 0.14 for the prednisolone group (Table 1, Fig. 3b).
Regarding the stiffness, significant differences were
generated (p = 0.030) between the control and diclofenac
groups. In detail, the stiffness of experimental bones
revealed 122.44 ± 81.16 N/mm for the controls, 57.31 ±
31.11 N/mm for the diclofenac group and 86.63 ±
60.45 N/mm for the prednisolone group (Table 1,
Fig. 3c). The percentage of the intact stiffness exhibited
0.24 ± 0.16 in the control group, 0.13 ± 0.10 in the diclo-
fenac group and 0.19 ± 0.14 in the prednisolone group
(Table 1, Fig. 3d).
μCT and histological examination
Nineteen animals were eligible for μCT and histology.
Table 1 Biomechanical parameters
Mean ± SD Mean difference (95 %-CI) p-value
Breaking load D 61.97 ± 24.91 D vs P 7.67 (-18.45 – 33.79) 0.543
P 54.30 ± 28.68 D vs K -15.68 (-48.20 – 16.84) 0.323
K 77.65 ± 41.82 P vs K 23.35 (-8.81 – 55.51) 0.144
% of intact load D 0.30 ± 0.12 D vs P 0.01 (-0.12 – 0.13) 0.934
P 0.29 ± 0.14 D vs K -0.06 (-0.20 – 0.07) 0.345
K 0.36 ± 0.16 P vs K 0.07 (-0.06 – 0.20) 0.297
Stiffness D 57.31 ± 31.11 D vs P -29.32 (-74.53 – 15.89) 0.188
P 86.63 ± 60.45 D vs K -65.13 (-122.81 – -7.45) 0.030*
K 122.44 ± 81.16 P vs K 35.81 (-28.18 – 99.79) 0.256
% of intact stiff-ness D 0.13 ± 0.10 D vs P -0.06 (-0.18 – 0.06) 0.321
P 0.19 ± 0.14 D vs K -0.10 (-0.23 – 0.03) 0.107
K 0.24 ± 0.16 P vs K 0.05 (-0.09 – 0.18) 0.481
D = diclofenac (n = 8), P = prednisolone (n = 11), K = control (n = 11). Entries marked with *represent significant differences between therapy groups
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BV was the most objective parameter with which to
assess the effective, i.e. absolute, callus volume (peri-
and endosteal) without the original cortical bone. The
control group exhibited a significant higher BV than the
diclofenac group (67.19 ± 14.90 vs. 47.05 ± 15.67, p =
0.037). Prednisolone generated the highest callus volume
(73.79 ± 17.23), which was significantly higher than that
of the diclofenac group (p = 0.015, Table 2, Fig. 4a). With
respect to the TMD, very homogeneous results were evi-
dent throughout the groups, except for the SD of the
diclofenac group: the latter showed an outlier (52.91)
that strongly influenced the mean and SD (SD control =
14.81 and SD prednisolone = 9.99) (Table 2 and Fig. 4b).
BMC represents density x volume. It exhibited analo-
gous significances and trends in values to those for BV
(Table 2 and Fig. 4c).
Structural parameters uniformly describe and quantify
the microarchitecture of specimens (Table 2).
The SMI of the control group showed no relevant dif-
ference from the diclofenac group (p = 0.553). Prednisol-
one showed the smallest mean (-1.30 ± 0.72). This was
significantly reduced compared with that of the diclofe-
nac group (0.08 ± 0.72, p = 0.006) (Table 2 and Fig. 4d).
With respect to the mean and SD of DA, all three
groups here were very homogeneous without relevant
differences (Table 2 and Fig. 4e). The mean of BS in the
control group (1636.83 ± 340.78) was considerably
higher than that in the diclofenac group (1282.18 ±
288.17, p = 0.073). In contrast, the mean of BS in the
control group was only slightly higher than that of the
prednisolone group (1618.80 ± 398.72, p = 0.935, Table 2
and Fig. 4f ). With respect to Tb. Th., a significant differ-
ence (p = 0.023) was seen between the control group
(mean = 0.0983 ± 0.003) and the diclofenac group (mean
= 0.0937 ± 0.003) (Table 2 and Fig. 4g).
Histological findings further supported the radio-
graphic evidence. The control group showed bony callus
in the area of the fracture gap analogous to the prednis-
olone group in 67 % of the samples. In contrast, the
diclofenac group showed bony callus in only 29 % of the
samples in the area of the fracture gap (Fig. 5 left dia-
gram). Additionally, we investigated cartilage and fibrous
connective tissue. In the prednisolone group, the least
cartilage was seen within the fracture gap, whereas 50 %
of the samples still showed fibrous connective tissue.
Both the control group and the diclofenac group gener-
ated relatively more cartilage than bone. Fibrous con-
nective tissue as poor-quality tissue was detected least
frequently within the fracture gap of the femura of the
Fig. 3 Biomechanical values as means ± SD and dotplot of (a) breaking load and (b) % of intact load, (c) stiffness and (d) % of intact stiffness.
Mean differences and significances are shown in Table 1
Table 2 μCT callus parameters
Mean ± SD Mean difference (95 %-CI) p-value
BV D 47.05 ± 15.67 D vs P -26.74 (-47.15 – -6.33) 0.015*
P 73.79 ± 17.23 D vs K -20.14 (-38.86 – -1.42) 0.037*
K 67.19 ± 14.90 P vs K 6.60 (-14.17 – 27.38) 0.494
TMD D 648.10 ± 52.91 D vs P 6.04 (-42.99 – 55.08) 0.776
P 642.06 ± 9.99 D vs K 12.62 (-36.68 – 61.92) 0.565
K 635.48 ± 14.81 P vs K 6.58 (-9.98 – 23.14) 0.391
BMC D 30.01 ± 9.58 D vs P -17.27 (-29.92 – -4.61) 0.012*
P 47.28 ± 10.76 D vs K -12.52 (-23.63 – -1.41) 0.031*
K 42.54 ± 8.61 P vs K 4.75 (-7.87 – 17.36) 0.420
SMI D 0.08 ± 0.72 D vs P 1.38 (0.50 – 2.27) 0.006*
P -1.30 ± 0.72 D vs K 0.30 (-0.81 – 1.42) 0.553
K -0.22 ± 1.01 P vs K -1.08 (-2.22 – 0.06) 0.062
DA D 1.15 ± 0.03 D vs P -0.02 (-0.07 – 0.02) 0.258
P 1.17 ± 0.04 D vs K -0.03 (-0.08 – 0.02) 0.258
K 1.18 ± 0.05 P vs K 0.00 (-0.06 – 0.05) 0.877
BS D 1282.18 ± 288.17 D vs P -336.62 (-779.83 – 106.59) 0.120
P 1618.80 ± 398.72 D vs K -354.66 (-748.85 – 39.54) 0.073
K 1636.83 ± 340.78 P vs K -18.04 (-496.72 – 460.65) 0.935
Tb. Th. D 0.094 ± 0.003 D vs P -0.005 (-0.011 – 0.001) 0.114
P 0.099 ± 0.006 D vs K -0.005 (-0.008 – -0.001) 0.023*
K 0.098 ± 0.003 P vs K 0.000 (-0.006 – 0.007) 0.878
D = diclofenac (n = 7), P = prednisolone (n = 6), K = control (n = 6). Entries
marked with *represent significant differences between therapy groups
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control group (33 %). In the diclofenac group, in which
occasionally diastases of the fracture gap were observed
(Fig. 5a), fibrous connective tissue (Fig. 5b) was detected
the most, at 57 %. Bone resorption areas were detectable
at the cortical bone, the fracture site and the periosteal
callus junction (Fig. 5a and b). Furthermore, a (negative)
ratio of bone/cartilage/connective tissue (29 %/57 %/
57 %) was evident in this group (Fig. 5 left diagram).
With regard to the bony bridging of the fracture gap
(Fig. 5 right diagram), the control group was more suc-
cessful (33 %) than the prednisolone group (17 %, des-
pite the high callus BV detected via μCT, Fig. 4a) and
the diclofenac group, respectively (14 %). Figure 5c
shows a representative sample of the prednisolone group
with osteocondral bone union and active new bone for-
mation indicating that endochondral ossification had
occurred, although the outer periosteal mineralised
callus did not bridge the gap, in contrast to that of the
control group (Fig. 5d).
Figure 6 shows a synopsis of the modalities of group B
(histology/μCT).
Discussion
Numerous disputes and limited data exist on bone heal-
ing with regard to the use of diclofenac and prednisol-
one. Possible causes for these problems are the applied
evaluation methods that are no longer considered suffi-
cient by today’s standards. Therefore, our aim was to
evaluate the qualitative and quantitative structural prop-
erties of the fracture callus in vivo via a combination of
biomechanics, micro-CT and histology.
Additional to the expected effects of each drug, the
timepoint in our study was chosen based on joint con-
sideration of the time course of rat callus fracture heal-
ing after 21 days [10, 28]. At that time, callus formation
is not yet finished and stable and significant differences
can be detected [29].
The diclofenac dose of 5 mg/kg body weight per day was
taken from the literature. Previous publications have shown
that a dose of 2.5 times (compared with the human dose of
2 mg/kg body weight) for the rat is necessary to generate
human equivalent pharmacological data [2, 15, 30].
The diclofenac group showed significantly lower
values for BV and BMC compared with the control and
prednisolone groups. Occasionally, we observed dia-
stases of the fracture gap. Histologically, only 29 % of
the samples showed mineralised callus in the area of the
fracture gap. However, the most common tissue within
the gap was fibrous connective tissue (57 %) indicating
impairment of fracture healing. Our results are concord-
ant with those of Krischak et al. who have studied this
phenomenon histologically. Both the bony percentage in
the area of the fracture gap and the fraction of bony
bridges were decreased, whereas the proportion of cartil-
age was increased [14]. Likewise, Tiseo et al. showed a
delay of bone remodelling, since the mineralised part of
Fig. 4 μCT values as means ± SD and dotplot of (a) BV, (b) TMD, (c) BMC, (d) SMI, (e) DA, (f) BS and (g) Tb. Th.. Mean differences and significances
are displayed in Table 2
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tissue within the callus was low and even decreased over
time (by 2-4 weeks) [31]. However, the two studies only
evaluated histological samples and did not focus on the
3D structural parameters of bone [11]. Our results sub-
stantiate the inhibiting influence of diclofenac on frac-
ture healing. New bone formation seems to be reduced
by diclofenac, whereas resorption seems to be increased.
Similar density values were determined between the
groups. If, in spite of similar TMD values, different SMI
values are detected, then the SMI reveals that different
trabecular structures are present. Values of zero and
negative values represent a more stable plate-like struc-
ture, whereas higher values indicate a less stable rod-like
structure. In the dioclofenac group, the SMI was the
highest (0.08 ± 0.72) and took a positive value only in
this group. This indicates the presence of less stable
bone in the diclofenac-treated group with a reduced cap-
acity to adapt load [32]. Furthermore, the trabecular thick-
ness was significantly reduced by diclofenac compared
with the control group implying a weaker network. Previ-
ous studies applied mainly conventional radiological (or
peripheral quantitative computed tomography = pQCT),
histological and/or biomechanical results without being
able to detect 3D trabecular structures [2, 14, 15]. Thus,
with regard to our results, not only the reduced amount
of bone substantiates the inhibiting influence of diclofenac
on fracture healing, but also the obvious changes in the
3D network of the callus strongly indicate the impairment
of bone remodelling.
With respect to prednisolone, the dose of 0.5 mg/kg
body weight per day to generate human equivalent
pharmacological data was taken from the literature [33].
Fig. 5 Representative histological images of fracture sites of the diclofenac (a and b), prednisolone (c) and control (d) groups. Each section is
oriented with the cortical bone on the bottom, periosteal fracture callus on the top and fracture site in the middle. Magnification 40 × (a, b, d) or
25 × (c). Scale bar: 500 μm. Left diagram: % of samples with the respective tissue within the fracture gap; right diagram: % of samples with bony
fracture gap bridging. The diclofenac-treated rats often developed areas of high bone resorption (denoted by arrows) at the CB, the F and the
periosteal callus junction. A shows a gap without any signs of a union. Note the lack of CA. B shows a fibrous bone union. In the prednisolone
group (c), osteocondral bone union and active new bone formations were detected indicating that endochondral ossification had occurred, al-
though the periosteal OC did not bridge the gap. Generally, calluses contained minor amounts of cartilage, but in half of the samples, residual
FCT was still detectetable (left diagram). D shows a sample with OC only and complete union with trabecular structure (right diagram). The normal
fatty BM was replaced by bone, the AB seen in D is an artifact of the embedding procedure. Staining: LL (bone: red, cartilage: blue; fibrous connective
tissue: pale blue to grey/white). CB = original cortical bone, OC = osseus callus, CA = cartilage, CC = calcified cartilage, WB =woven bone, FCT = fibrous
connective tissue, F = fracture site, AB = air bubble, BM= bone marrow, arrow= zone of resorption
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To date, there is no clear evidence that the fracture heal-
ing is restricted in patients who are under glucocorticoid
medication [34]. Controversially, long-term medication
of 5.5 weeks up to 3.5 months led to impaired fracture
healing in rabbits (ulnar osteotomy) and rats (closed/
open fracture of the femur) [7, 10, 19, 33–35], whereas
short-term medication of 3-4 days in a femural osteot-
omy model of the rat did not affect the biomechanics or
histology [16, 36]. Here, the applied doses ranged from
0.02 mg/kg to 2 mg/kg body weight per day.
The data from our prednisolone group revealed no
relevant difference in the elevated BV in comparison
with that of the control group. However, the value was
significantly higher than that of the diclofenac group.
Concordantly, the prednisolone group of a recent rat
femur fracture study showed an increased total bone
area histologically generated by an increase of the woven
bone, whereas the lamellar bone showed decreased
values [34]. Compared with the control group, the au-
thors described a slow remodelling of woven bone to
lamellar bone within the callus; this is equivalent to a
delay of fracture healing. However, since the authors did
not undertake biomechanics or 3D tomography, no clear
evidence could be drawn with regard to functional in-
competence. Weinstein et al. have demonstrated de-
creased osteoclast production, resulting in a reduction of
bone remodelling [8].
Thus, in contrast to NSAIDs the effect of steroids on
fracture healing seems to be more complex. Via inhib-
ition of phospholipase A2, prednisolone acts in the same
pathway as diclofenac does, finally reducing prostaglan-
dins locally. Additionally, a direct transcriptional down-
regulation of osteoprotegerin (OPG) occurs in osteoblast
linages, independent of their respective differentiation
[37, 38], whereas RANKL (Receptor activator of nuclear
factor (NF-) kB ligand) is upregulated [39]. Recently, a
study by Pichler et al. showed an increased RANKL ex-
pression in rats with prednisolone-induced osteoporosis
leading to an enhanced RANKL/OPG ratio [40]. Inter-
estingly, these effects could be reversed by physical
Fig. 6 a and b illustrates intraoperative plain X-ray controls via c-arm after intramedullary pinning and after the fracture. The second row displays
(c = dorsal, d = ventral) macroscpic, (e) scout view and (f) 3D coronar μCT (callus blue and semitransparent, original cortical bone grey) post mor-
tem controls. g shows a histological overview image (10×, details: Fig. 4a) and h a corresponding half-sliced 3D coronar μCT reconstruction. All
images represent the same specimen of the diclofenac group. Macroscopically, no diastasis of the fracture gap is detectable. However, the tissue
type can only be assumed. In contrast, radiologically, a diastasis of the fracture gap and a dislocatio ad latum with wedge-shaped defects
is seen. Additionally, histology demonstrates fibrous connective tissue
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activity leading to protective effects not only on bone,
but also on articular cartilage [41].
In accordance, our histological results revealed bony
fracture gap bridging in only 17 % of the prednisolone
group (control group: 33 %). In 50 % of the specimens,
fibrous connective tissue in the area of the fracture gap
(control group: 33 %) was still present, whereas cartilage
was detected rarely compared with the control group.
Gerstenfeld et al. described a transition from cartilage to
bone after 21 days in physiological fracture healing in
the rat and, similarly, the residual presence of connective
tissue in our prednisolone group can be interpreted as a
delay of fracture healing [42]. With regard to the struc-
tural parameters assessed by μCT in our study, the SMI
of the prednisolone group was significantly lower (-1.30)
than the SMI of the diclofenac group and a trend was
shown compared with the control group. Negative
values represent dense stable trabecular structures. The
Tb. Th. was significantly higher compared with the
diclofenac group implying a stronger network. Thus,
unlike diclofenac, the prednisolone-influenced callus
seemed to be more stable, thereby epitomising the de-
layed remodelling via osteoclast inhibition. Nevertheless,
simultaneous osteoblast inhibition resulted in an impair-
ment of the bridging callus, together resulting in lower
union rates. Thus, biomechanically, a markedly de-
creased breaking load and stiffness of the prednisolone
group was shown compared with the control group. His-
tologically, the alterations were confirmed: in spite of an
adequate callus volume, even the outer periosteal miner-
alised callus did not bridge the gap in most of the cases.
However, this is the area in which cortical bridging nor-
mally begins and, since it is located far from the geomet-
ric centre of the bone, it is considered to be responsible
for the majority of weight bearing [14, 29].
Conclusion
Summarised, diclofenac and prednisolone showed sub-
stantial impairment of fracture healing in the rat fracture
model. Therefore, in particular for patients with risk fac-
tors (diabetes mellitus, smoking), these drugs should be
avoided when fracture healing or spine fusion is the pur-
pose of treatment. Because the administration of pred-
nisolone results in impaired delayed fracture healing in a
different way from that of NSAR application, further
basic research is needed to determine the causes for this
and, thus, to develop new causal therapy approaches.
However, findings in animal studies cannot be extrapo-
lated directly to humans and so studies are necessary to
investigate the possible (side)-effects of these medica-
tions in patients [43]. Furthermore, an important aspect
would be to determine the cut-off duration for the “safe”
administration of diclofenac and prednisolon in the clin-
ical setting of fracture healing.
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